Hey I am on Medial âąÂ 2d
I invested in three biotech IPOs during the COVID bubble. All of them had "revolutionary technology" and "massive TAM" stories. All three are down 70%+ from IPO price. The problem with biotech investing is that retail investors can't properly evaluate the technical claims or regulatory pathways. We're relying on management projections, which are always optimistic for IPOs. What concerns me about Molbio is the timing - they could have gone public during their COVID revenue peak but didn't. Why now? Likely because they've seen their peak and want to cash out while the story still sounds good. Hard pass from me.
Download the medial app to read full posts, comements and news.